Navigation Links
Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Date:10/2/2007

ch programs focusing on human and organizational communication to reduce chronic disease and cancer health disparities affecting Hispanics/Latinos and other populations. She has authored numerous peer-reviewed articles and is frequently invited to speak at scientific meetings.

Ramirez is a former member of the National Cancer Advisory Board and the National Heart, Lung, and Blood Advisory Council of the National Institutes of Health.

"Dr. Ramirez's unique expertise and keen insight has proven invaluable to Komen identifying and addressing breast health disparities among specific population groups, including Hispanic and Latino people. As a member of its Scientific Advisory Board (SAB), Dr. Ramirez will be instrumental in Komen's ability to reach even more deeply into areas of our society that remain medically underserved," said Dr. Winer.

In addition to Dr. Winer and Dr. Ramirez, the SAB includes the following physicians and researchers:

-- Melissa L. Bondy, Ph.D., professor of epidemiology at the University of

Texas M.D. Anderson Cancer Center, Houston, and director of the

Childhood Cancer Epidemiology and Prevention Center, a collaborative

program between M.D. Anderson Cancer Center, Baylor College of Medicine

and Texas Children's Hospital.

-- Powel Brown, professor of medicine, Baylor College of Medicine;

associate director of cancer prevention and director of cancer

prevention and populations studies program, Dan L. Duncan Cancer

Center; and associate director of research at the Breast Care Center

Baylor-Methodist.

-- H. Kim Lyerly, M.D., George Barth Geller Professor of Research at Duke

University, Durham, N.C.; director of the Duke Comprehensive Cancer

Center and principal investigator of the Duke Specialized Program in

Research Excellence (SPORE).

-- George W. Sledge, M.D., Ballve-Lantero Professor of Oncology and


'/>"/>

SOURCE Susan G. Komen for the Cure
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Scientific markers of aging described
2. A Settlement Over Stem Cell Controversy Through Scientific Research
3. A Scientific Explanation For Out Of Body Experience
4. PUFA Good For Heart: Gets The Scientific Seal
5. Forensic Phonetics – Scientific Solution for Legal Problem
6. Old Indian Advice Has A Scientific Backing Now!
7. India To Highlight Its Scientific Achievements
8. Thumbs up in weight loss for vegetarian diets: scientific review
9. Scientific Research in a War Zone
10. Unscientific Depression Drugs aplenty in Health Stores
11. No Scientific Evidence to Support Drug Safety Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6New Robotic Arm Has Softer Surgical Touch 55753 1New Robotic Arm Has Softer Surgical Touch 55753 2Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 1Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 2Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 3Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 1Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 2Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 3
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2